Elypta, part of the Accelerator at Sahlgrenska Science Park, raises $21 million Series A to develop metabolism-based multi-cancer early detection test.
Publish date:2022-06-22
Elypta is a Swedish diagnostics company aiming to commercialise the first metabolism-based liquid biopsy for early detection of any cancer. Elypta has been part of the Accelerator as a startup since November 2019.
In this short period of time Elypta has reached a big goal as a company and is closer to a future of significant results of cancer prevention.
”We are very excited to now be able to conclude the development phase of our two lead products. It’s also great to have added Bonnier Ventures to our already excellent group of owners,” says Karl Bergman, CEO, Elypta.
The company will use the capital to develop and validate blood and urine tests for Multi-Cancer Early Detection (MCED) in adults with no symptoms of cancer and for detection of recurrence in kidney cancer patients. The tests are based on the exhaustive profiling of human glycosaminoglycans, also known as the GAGome, as biomarkers of cancer metabolism, an approach pioneered by Elypta based on research performed at Chalmers University of Technology by founders Francesco Gatto and Jens Nielsen.
